Rolling coverage of the latest economic and financial news
Pharmaceuticals news: AstraZeneca is investing $2bn in biopharmaceutical oncology company Summit Therapeutics, as part of a tie-up to jointly develop and test anti-cancer drugs.
Announcing the deal, AstraZeneca says the two companies will collaborate on a series of studies testing their cancer treatments together.
“A core pillar of our oncology strategy is to broaden the reach of our ADC portfolio as the backbone of treatment across tumour types with combinations alongside next-generation immunotherapies.
Bispecifics targeting PD-1 and VEGF are rapidly advancing in development and have the potential to improve on current immunotherapies, particularly in lung, breast and gastrointestinal cancers. This opportunity to combine ivonescimab with AstraZeneca’s ADC portfolio, including with Sone-Ve, could enable new regimens that raise the bar for patients with cancer across the treatment landscape.”
“Our development of highly advanced models, platforms, and applications and expansion of use cases could further increase the risk that our models cause harm.”
“Potential model awareness of our evaluation efforts creates a significant limitation on our ability to assess model safety.”
